Study: Unapproved copies of Lilly's obesity drug underperform

A new study indicates that patients using unapproved versions of Eli Lilly's retatrutide, a triple agonist, experience significantly less weight loss than those on the authentic drug. The authentic drug has shown up to 25% weight loss in Phase 3 trials, but gray-market alternatives appear to be less effective. The findings highlight risks associated with sourcing medications outside regulated channels.